Alpha Cognition Inc. announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective April 7, 2025. Dr. Wills brings over four decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development and corporate strategy.
Dr. Wills' extensive background includes leadership roles at Johnson & Johnson and board positions at other pharmaceutical companies. His expertise is expected to be instrumental as Alpha Cognition advances the commercial launch of ZUNVEYL and progresses its sublingual program for Alzheimer’s disease.
Concurrently, John Havens notified the company of his intention not to seek re-election to the Board for 2025 forward. The company will initiate a search for a new independent board member to fill the vacancy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.